Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT01826708

Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations

Conditions: Balanced Chromosomal Translocation

Sex: All
Healthy volunteers: No
Phase: EARLY_PHASE1
Enrollment: 10
Sponsor: University Hospital, Montpellier

Location: Laboratory of Chromosomal Genetics - Universitary Hospital Montpellier

Summary

For every child with developmental delay, the investigators do a constitutional karyotype. This karyotype can reveal an apparently balanced chromosomal rearrangement (no visible loss or gain of genetic material), such as a translocation between two or more chromosomes of accidental occurrence (not transmitted by parents). However, an apparently balanced translocation does not explain the phenotype of the child. Among the hypotheses that could explain the child's symptoms, there is the possibility of another chromosomal abnormality at the translocation breakpoints, another defect elsewhere on the chromosomes or gene disruption at or near the breakpoints. Because the resolution of a constitutional karyotype is limited, these microanomalies can go undiagnosed. The goal of this study is to look for a microanomaly on a chromosome using a technology of higher resolution than that of the conventional karyotype. The proposed study uses DNA microarray technology on DNA extracted from blood lymphocytes to perform high-resolution analysis of all chromosomes to search for an unbalanced microrearrangement (such as loss or gain of chromosomal material). If no microrearrangement is found, the investigators will pursue by looking for a gene disruption defect at or near the breakpoints involved in the translocation. This will be done by first isolating the chromosomes involved in the translocation by flow cytometry and then hybridizing each of the isolated chromosomes on a new microarray. The purpose of this study is to find a possible cause to explain the phenotype (microrearrangement or gene disruption).

Eligibility Criteria

Inclusion Criteria: * patient with syndromic psychomotor delay * patient with a apparently balanced de novo chromosomal translocation * patient with health insurance * informed consent signed by patient or by parents or by the legal representative for children Exclusion Criteria: * patient with an inherited translocation

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT01826708). StuddyBuddy aggregates publicly available trial information.